Frits van Rhee

,

UAMS Myeloma Center Hits Impressive Milestone, Sees 1000th Article Published

,

By Nathan Tidwell

Researchers and physicians with the Myeloma Center at the University of Arkansas for Medical Sciences (UAMS) recently published their 1,000th article, an impressive milestone that demonstrates the center’s high level of scholarship.

“This is a remarkable achievement by our amazing Myeloma Center physicians and researchers,” said Frits van Rhee, M.D., Ph.D., clinical director of the Myeloma Center, part of the Winthrop P. Rockefeller Cancer Institute.

Sandy Mattox, MNSc, RN, who tracks publications for the Myeloma Center, notes that No. 1,000 was a paper published in the July 11, 2023, issue of Blood Advances titled “Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.” It was co-authored by van Rhee and UAMS physicians and researchers Samer Al Hadidi, M.D.; Carolina Schinke, M.D.; John Shaughnessy Jr., Ph.D.; Sharmila Thanendrarajan, M.D.; Mauricio Zangari M.D.; and Fenghuang (Frank) Zahn, M.D., Ph.D.

UAMS Myeloma Center Hits Impressive Milestone, Sees 1000th Article Published

,

UAMS Offering Revolutionary CAR T-Cell Therapy for Myeloma Patients

,

By Linda Haymes

The Myeloma Center at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) is offering a new cutting-edge immunotherapy treatment for myeloma patients.

UAMS is the first and only medical facility in Arkansas approved to provide cellular therapy to myeloma patients.

“This is exciting because this is the first cellular therapy product commercially available for myeloma patients,” said Myeloma Center clinical director Frits van Rhee, M.D. Ph.D.

https://news.uams.edu/2021/08/09/uams-offering-revolutionary-car-t-cell-therapy-for-myeloma-patients/